CION Ameerpet
Ovarian cancer spreads in a way most other cancers do not. It rarely travels through the bloodstream at first — instead it sheds cells into the fluid that circulates around the abdominal cavity, and those cells settle on the surfaces that fluid passes over. Once you understand that one mechanism, almost everything else about this disease makes sense.
Most cancers spread by invading a blood vessel or a lymphatic channel and travelling somewhere else. Ovarian cancer mostly does something simpler and stranger. The ovaries and fallopian tubes are not sealed inside an organ capsule — they sit open in the abdominal cavity, bathed in a small volume of peritoneal fluid. A tumour on the surface of an ovary, or on the fimbrial end of a fallopian tube, sheds cells directly into that fluid.
So the honest answer to how does ovarian cancer spread is: by falling, and then by floating. Shed cells are carried on the currents of peritoneal fluid, which is drawn upward by the movement of the diaphragm with every breath and pulled back down by gravity. Wherever that fluid slows or pools, cells settle and implant on the surface beneath. This is called transcoelomic seeding, or peritoneal spread, and it is by far the dominant route in ovarian, fallopian tube and primary peritoneal cancer.
The two familiar routes still exist, but they matter later. Lymphatic drainage carries cells along the ovarian vessels to the pelvic and para-aortic nodes, which is why those nodes are assessed at surgery. Spread through the bloodstream to the liver tissue, the lungs, bone or brain does happen, but it is uncommon and generally a late event. A cancer that has covered the peritoneum has often never entered a blood vessel at all.
Cells shed into peritoneal fluid and implant on the surfaces it washes over: the omentum, the pelvic lining, the bowel surface, the paracolic gutters and the undersurface of the diaphragm. This is what “peritoneal spread” means, and it accounts for the great majority of ovarian cancer spread.
Cells travel along lymphatic channels that follow the ovarian blood vessels upward to the pelvic and para-aortic nodes, as high as the renal veins. It is usually silent. It shows up on a staging CT or in the nodes assessed during surgery rather than as a symptom.
Spread into the substance of the liver, into lung tissue, bone or brain requires the tumour to invade a blood vessel. In ovarian cancer this is uncommon and generally late, which is why the disease often stays within the abdominal cavity for a long time.
Peritoneal spread is not random — it follows the plumbing. Peritoneal fluid circulates around the abdomen in a predictable pattern, drawn upward along the paracolic gutters by the movement of the diaphragm with each breath and pulled back down by gravity. In 1973 the radiologist Morton Meyers mapped where intra-abdominal seeding therefore lands: the pouch of Douglas behind the uterus, the right paracolic gutter, the space beneath the right hemidiaphragm and behind the liver, and the lower small-bowel mesentery near the ileocaecal junction. Half a century later those are still the first places a radiologist looks on a staging CT, and the first places a surgeon inspects in theatre. Source: Meyers MA, American Journal of Roentgenology (1973), on the distribution of intra-abdominal malignant seeding; NCCN Ovarian Cancer guidelines; WHO Classification of Tumours, Female Genital Tumours.
This is the map behind the words on a CT report. Read alongside your own report, it usually turns an alarming paragraph into something specific and answerable.
| Site | How it gets there | What it tends to cause |
|---|---|---|
| Omentum | The fatty apron hanging in front of the bowel acts as a filter for peritoneal fluid, so seeded cells collect there first and in bulk. | A thickened, matted sheet that radiologists call omental cake. It causes bloating, a firm upper-abdominal fullness and feeling full quickly. |
| Pelvic peritoneum and pouch of Douglas | The lowest point of the abdominal cavity, where fluid and shed cells pool under gravity. | Pelvic pressure and pain, urinary frequency, a change in bowel habit, and a nodular ridge a doctor can sometimes feel on examination. |
| Paracolic gutters and diaphragm surface | Fluid is drawn up the channels beside the colon towards the diaphragm every time you breathe in. | Often no symptom at all until ascites develops. Deposits under the diaphragm can cause shoulder-tip discomfort or breathlessness. |
| Surface of the bowel and its mesentery | Deposits implant on the outer serosal coat of the small and large bowel rather than growing inside it. | Colicky pain, altered bowel habit, nausea and early fullness. Extensive disease can tether bowel loops and cause obstruction. |
| Uterus, bladder and rectum | Direct extension of the primary tumour into neighbouring pelvic organs. | Pelvic pain and pressure, urinary urgency, constipation or a constant urge to open the bowels. This is what defines FIGO stage II. |
| Pelvic and para-aortic lymph nodes | Lymphatic channels running alongside the ovarian vessels, upward to the level of the renal veins. | Usually silent. Found on CT, or in the nodes assessed at surgery. Rarely, a palpable groin or neck node is the first sign. |
| Liver — surface versus inside | Deposits on the liver capsule arrive by peritoneal seeding. Deposits inside the liver tissue arrive through the bloodstream. | The distinction changes the stage: capsule deposits remain stage III, while deposits within the liver substance are stage IVB. |
| Pleural cavity, and rarely lung, bone or brain | Cells cross the diaphragm through tiny lymphatic channels into the chest; distant organs are reached through the bloodstream. | Breathlessness from a pleural effusion. A malignant pleural effusion confirmed on cytology defines stage IVA. |
*This is the pattern seen most often, not a sequence every cancer follows. Your own report may list two of these sites or six, and the number alone does not decide what treatment can achieve.
The mechanism is not trivia. It explains the symptoms, the stage at diagnosis, the size of the operation, and the reason chemotherapy carries so much weight in ovarian cancer.
Disease spreading across the lining of the abdomen does not press on one structure and produce one clear symptom. It irritates a wide surface and interferes with the absorption of fluid, so what a woman notices is bloating, a tight waistband, feeling full after a few mouthfuls, a change in bowel habit, or needing to pass urine more often. Every one of those has a dozen harmless explanations.
This is why ovarian cancer was mislabelled a silent disease for so long. It is not silent. It produces symptoms that are real but non-specific, generated by a mechanism spread thinly over a large area rather than concentrated in one place. The complete ovarian cancer guide sets out the symptom pattern that is worth acting on.
For a cancer to be caught at stage I, something has to announce it while it is still confined to the ovary or tube. Peritoneal seeding can begin from a tumour that is still small, and there is a great deal of room in the abdominal cavity for deposits to accumulate before they cause trouble. By the time symptoms are persistent enough to prompt a scan, the disease is frequently already on the omentum and the pelvic lining.
That is also the reason no ovarian cancer screening programme works, for anyone, including women who carry a BRCA variant. Neither CA-125 nor ultrasound reliably detects this disease before it has seeded, and screening trials have not shown that surveillance saves lives. Anyone who tells you a yearly blood test protects you against ovarian cancer is mistaken.
An operation for a cancer that has seeded across surfaces cannot simply remove an organ. It has to strip disease from the peritoneal lining, remove the omentum, address involved lymph nodes, and sometimes take a segment of bowel or peel deposits off the diaphragm. The aim is to leave no visible disease behind, because how much residual disease remains is one of the strongest influences on how well the chemotherapy that follows performs.
This is specialist gynaecologic-oncology surgery. At CION it is coordinated with specialist gynaecologic-oncology surgeons at partner centres, where the procedure is performed and may be billed. Medical oncology runs in-house. We would rather say that plainly at the start than let you discover it at the billing counter.
Because the disease sits on surfaces bathed in peritoneal fluid rather than buried inside a solid organ, it is unusually accessible to drug treatment. Ovarian cancer is one of the most chemotherapy-sensitive of the common solid cancers, and platinum-based chemotherapy remains the backbone of treatment, whether it is given before surgery, after it, or both.
The same logic underlies intraperitoneal chemotherapy and HIPEC, where drug is delivered into the abdominal cavity to reach the peritoneal surfaces directly. These are selective options rather than routine ones, and at CION they are coordinated at specialist partner centres. Systemic chemotherapy and the rest of the ovarian cancer treatment pathway are delivered in-house.
Peritoneal deposits are often miliary — a fine scatter of implants a millimetre or two across, spread over a wide surface. CT resolves nodules reliably at around a centimetre, so a scan can genuinely underestimate how widely a cancer has seeded, particularly on the small-bowel mesentery and under the diaphragm.
That gap is why a diagnostic laparoscopy is sometimes done before major surgery: looking directly at the peritoneum answers the question of resectability that a CT could not. It is also why the final stage is assigned after surgery and pathology, not from the scan report you are holding today.
In many cancers, spread beyond the organ of origin marks a decisive change in what treatment is trying to do. Ovarian cancer behaves differently. Disease scattered across the peritoneum is stage III, and stage III ovarian cancer is routinely treated with the intention of achieving complete remission, using surgery and chemotherapy together.
That does not make an advanced diagnosis a small thing, and nobody should pretend otherwise. But a report describing widespread peritoneal deposits is not the same sentence it would be in another cancer, and it is worth knowing that before you spend a night reading about metastatic disease in general.
None of these proves anything on its own, and some have ordinary explanations. Each is a reason to be seen rather than to watch and hope — and if you are already under treatment, to telephone your oncology team the same day.
A genuine, progressive increase in girth suggests ascites rather than bloating, and needs imaging promptly.
Colicky pain with vomiting and a silent bowel can mean obstruction. Go to hospital the same day rather than waiting for an appointment.
Persistent nausea, or feeling full after two or three mouthfuls for several days, needs assessment. Dehydration builds quickly and quietly.
Breathlessness that is new, or that forces you to sleep propped up, may indicate fluid in the chest or a tense abdomen pressing upward. Have it checked rather than adjusting your pillows.
One-sided leg swelling can indicate a clot, which is commoner in ovarian cancer than in most cancers. Ask for same-day assessment.
Abdominal or pelvic pain that is sharp, severe, or steadily worsening over hours to days is not something to sit out at home.
If you have not been diagnosed and are here because of persistent bloating or abdominal swelling, start with the symptom guidance in the complete ovarian cancer guide rather than assuming the worst — most of these symptoms turn out to have benign causes.
Bring your scan and biopsy reports to a free 45-minute consultation. You will leave knowing which surfaces are involved, what that means for the order of treatment, and what the next decision actually is.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
No referral needed and no cost for the first consultation. Chemotherapy, maintenance therapy and BRCA and HRD testing are delivered in-house — see how ovarian cancer treatment in Hyderabad is organised.
There is no single test that maps peritoneal disease. The picture is assembled in a sequence, and the definitive answer is usually not available until after surgery.
How long the symptoms have been present, how quickly the abdomen has changed, whether breathing or eating is affected. An abdominal examination looks for distension, free fluid and a palpable omental mass; a pelvic examination assesses the pouch of Douglas, where deposits are often first felt. This conversation shapes every test that follows, which is why CION consultations run to 45 minutes rather than five.
The workhorse of staging. It shows omental thickening, peritoneal nodules above about a centimetre, ascites, enlarged pelvic and para-aortic nodes, pleural fluid, and any deposits within the liver substance. It is good at defining the overall pattern, and honest about its limits: fine miliary seeding on the mesentery and diaphragm can be invisible to it.
A blood marker usually raised when there is significant peritoneal disease, and useful afterwards for tracking response to treatment. It is not a map. It cannot tell you which surfaces are involved, it rises in many benign conditions, and it can be only modestly raised in extensive disease. Treated as a trend rather than a single number, it is genuinely informative.
If there is ascites, draining some of it does two jobs at once: it relieves the pressure and sends cells for cytology. Where fluid is absent, an image-guided core biopsy of an omental or peritoneal deposit gives the histological subtype and the tissue needed for HRD testing. Germline BRCA testing and genetic counselling are offered to everyone diagnosed, and are delivered in-house at CION.
PET-CT is not a routine staging test in newly diagnosed ovarian cancer, because it adds little to a good contrast CT for peritoneal disease. It is more useful where recurrence is suspected and conventional imaging is equivocal. It is delivered at partner diagnostic centres and coordinated by CION rather than performed in-house.
Where resectability is uncertain, a diagnostic laparoscopy allows the peritoneum to be inspected directly and a decision made between surgery first and chemotherapy first. The definitive stage is assigned after cytoreductive surgery and pathology. That surgery is coordinated with specialist gynaecologic-oncology surgeons at partner centres, with the plan agreed at a tumour board beforehand.
*Nothing on this list is ordered as a routine panel. Each step is chosen because the previous one left a specific question unanswered.
Most people arrive at this page holding a CT report they have already read four times. The words are technical, the tone is neutral, and nobody has sat down and explained which of those findings changes anything. That explanation is the single most useful hour in the whole process, and it is where a first consultation should start.
Your first consultation at CION is free and runs to about 45 minutes. We go through the report site by site, say plainly which findings drive the treatment decision and which are incidental, and set out the realistic sequence — surgery first, or chemotherapy first, and why. Every case is discussed at a tumour board rather than decided by one doctor working alone.
On capability we are straightforward. Chemotherapy, maintenance therapy, genetic counselling, BRCA and HRD testing, nutrition support and follow-up are delivered in-house at CION, across 35+ centres in Telangana and Andhra Pradesh, so most of your treatment can happen near where you live. Cytoreductive surgery, HIPEC, intraperitoneal chemotherapy and PET-CT are delivered at specialist partner centres, coordinated by us and billed there. You should know that at the start, not halfway through.
Free, unhurried, and long enough to go through a staging report properly rather than summarising it in two sentences.
Medical oncology, surgical input, imaging and pathology in one room, deciding the order of treatment together instead of one clinician deciding alone.
Chemotherapy, maintenance therapy, genetic counselling and BRCA and HRD testing, delivered by CION across 35+ centres.
Debulking surgery, HIPEC and intraperitoneal chemotherapy are performed at specialist partner centres and may be billed there. Decisions for healing, not billing.
Extent of spread is one of several things that shape the outlook, alongside tumour subtype and grade, how completely the disease can be removed at surgery, how the cancer responds to platinum-based chemotherapy, BRCA and HRD status, and general fitness. Two women with near-identical CT reports can have very different courses because of those other factors. That is the honest reason no specialist will offer you a number in the first consultation.
You will find stage-by-stage survival percentages online, and they deserve caution. Most are drawn from cohorts treated years ago, they average across substages and histological subtypes that behave quite differently, and they mix women whose surgery removed all visible disease with women whose surgery could not. They describe the past, and they describe a group.
The one comparison CION publishes is its own one-year survival alongside the national figure, so it can be checked rather than implied. For ovarian cancer, 81.0% of CION patients are alive at one year, against a national figure of 73.7%. That is one-year survival across the whole treated population — not a cure rate, and not a prediction for any individual.
CION ovarian cancer patients alive at one year from diagnosis. *One-year survival, CION treated population.
The comparable national figure for ovarian cancer. *One-year survival; national registry data.
It is not a cure rate and not your prognosis. Subtype, completeness of surgery, response to chemotherapy and BRCA or HRD status matter far more to any individual outlook.
*One-year survival rates. CION figures reflect CION's treated patient population; national figures are drawn from published Indian cancer registry data. Survival statistics describe groups, not individuals — discuss your own situation with your treating oncologist.
Mainly by seeding, not by travelling. The ovaries and fallopian tubes sit open inside the abdominal cavity rather than sealed within an organ, so a tumour on their surface sheds cells directly into the peritoneal fluid. That fluid circulates around the abdomen, drawn upward by the movement of the diaphragm and pulled back down by gravity, and the shed cells implant on whichever surfaces it washes over. This is called transcoelomic or peritoneal spread, and it is the dominant route. Lymphatic spread to the pelvic and para-aortic nodes is the second route, and spread through the bloodstream to organs such as the liver tissue, lungs or bone is uncommon and usually late.
The omentum, the fatty apron hanging in front of the bowel, is the commonest and usually the bulkiest site, because it acts as a filter for peritoneal fluid. Alongside it, deposits collect in the pouch of Douglas behind the uterus, which is the lowest point in the abdomen where fluid pools, and on the pelvic peritoneum. From there, fluid currents carry cells up the paracolic gutters to the undersurface of the diaphragm, and over the surface of the bowel and its mesentery. That is why a radiologist reporting a staging CT looks at those particular places first, and why they tend to appear in that order on the report.
It means deposits of cancer are sitting on the peritoneum, the thin membrane lining the abdominal cavity and covering the organs inside it. Your report may use other words for the same thing: peritoneal deposits, peritoneal nodules, peritoneal carcinomatosis, omental caking or omental thickening. It is spread across surfaces rather than growth into the substance of an organ. In FIGO terms, peritoneal spread beyond the pelvis is stage III, and stage III ovarian cancer is treated with the intention of achieving remission, using surgery and chemotherapy together. Ask your oncologist to walk you through your own report site by site rather than reading it alone at night.
It can, but this is the least important route and generally a late one. Spread through the bloodstream produces deposits inside the liver tissue, in the lungs, and occasionally in bone or brain, and it requires the tumour to invade a blood vessel. Most ovarian cancer never does this. The distinction matters for staging: deposits sitting on the outer capsule of the liver arrived by peritoneal seeding and remain stage III, while deposits within the liver substance arrived through the blood and are stage IVB. Those two findings can look similar in a one-line report and mean quite different things, which is worth clarifying with your team.
It varies far more than most people expect, and there is no reliable general answer. High-grade serous carcinoma, the commonest subtype, can seed the peritoneum from a primary tumour that is still small, which is one reason it is usually found at an advanced stage. Low-grade serous and mucinous cancers typically behave much more slowly. Speed also depends on grade, and on whether the tumour surface is involved or has ruptured. More useful than a timeline is the response to treatment: ovarian cancer is one of the most chemotherapy-sensitive of the common solid cancers, so widespread disease often shrinks substantially once treatment begins.
Yes, and it is worth knowing that. Peritoneal deposits are frequently miliary, meaning a fine scatter of implants a millimetre or two across over a wide surface, while CT resolves nodules reliably only at around a centimetre. Fine seeding on the small-bowel mesentery and under the diaphragm is where scans most often under-read the true extent. This is exactly why a diagnostic laparoscopy is sometimes performed before major surgery, so the peritoneum can be inspected directly and the question of resectability answered properly. It is also why the definitive stage is assigned after surgery and pathology rather than from the scan report.
Yes, and this is where ovarian cancer differs from most other cancers. Disease scattered across the peritoneum is stage III, and stage III is routinely treated with the intention of achieving complete remission, using cytoreductive surgery and platinum-based chemotherapy together, often followed by maintenance therapy. Even stage IV disease usually responds well to chemotherapy. That does not make an advanced diagnosis a small thing, and nobody should suggest it does. But the phrase it has spread carries a different weight here than in cancers that disseminate through the bloodstream, and it is worth understanding that before drawing conclusions from general reading about metastatic cancer.
The first consultation is free and runs to about 45 minutes, with no referral needed. CION delivers medical oncology in-house, which covers platinum-based chemotherapy, maintenance therapy, genetic counselling and BRCA and HRD testing, across more than 35 centres in Telangana and Andhra Pradesh, so most treatment can be given near where you live. Cytoreductive or debulking surgery, HIPEC, intraperitoneal chemotherapy and PET-CT are delivered at specialist partner centres, coordinated by CION and billed there, and we say so at the outset rather than leaving it to be discovered later. Every case is planned at a tumour board.